Dr. Linda Law serves as a Development, Medical, and Commercial Strategy Consultant at Ceramedix Inc. Leveraging her extensive background in medical affairs and international drug development, she plays a crucial role in guiding R&D initiatives and ensuring alignment with clinical, regulatory, and commercial goals.
With 25+ years of leadership experience in clinical development, Dr. Law has orchestrated numerous phase I-III trials and secured global approvals for drugs spanning diverse therapeutic areas. As Principal at BioHealthConsult, she has consulted for several cutting-edge biopharmaceutical companies, crafting clinical development strategies from preclinical through marketing stages, supporting fundraising efforts, and assessing in-licensing opportunities. Previously, she held leadership roles at Procter & Gamble Pharmaceuticals, overseeing drug development and medical affairs. She led teams that completed trials and supported approvals for Asacol 800, Intrinsa, and Xermelo, served as Medical Director in Medical Affairs for the record-breaking osteoporosis treatment Actonel, and oversaw scientific activities that captured 70% market share for GI products. She also spearheaded various post-marketing safety studies and managed strategic planning and protocol development for Phase I, II, and III trials in IBD, IBS, and carcinoid syndrome.
Dr. Law holds an MD from the University of Texas Health Science Center at Houston, an MBA from The Ohio State University, and a BA in biology from Rice University. She is board-certified in emergency medicine and in obesity medicine and maintains an active medical license.